Press Release Service

Sherlock at Apex of CRISPR-based Diagnostics after USPTO Grants Earliest Priority Patent

Preeminent IP position gives Sherlock freedom to operate and commercialize across multiple CRISPR business avenues.

- Feb. 22, 2023

Watertown, Mass., Feb. 21, 2023

Sherlock Biosciences, a company engineering biology to bring next-generation lab-quality diagnostic testing to the point of need, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent for the diagnostic use of the Cas12 enzyme, establishing Sherlock as the leader in CRISPR-based diagnostics with freedom to operate in the U.S. Sherlock has exclusive U.S. rights to the patent from Shanghai-based Tolo Biotech, plus additional intellectual property (IP) for Cas12 and Cas13 from the Broad Institute, giving the company the preeminent IP position in the space.

Read the PR here

Tags

HashtagArticleHashtagPress Release ServiceHashtagSherlock Biosciences, Inc.

News: Sherlock at Apex of CRISPR-based Diagnostics after USPTO Grants Earliest Priority Patent
News: Sherlock at Apex of CRISPR-based Diagnostics after USPTO Grants Earliest Priority Patent
CLINICAL TRIALS
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Huntington's Disease, (NCT05032196)
Sponsors:
Wave Life Sciences Ltd.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine